Ligand expanded Icagen’s collaboration with Roche to develop ion channel modulators for the treatment of neurological disorders

BY      |     May 29, 2020

Ligand Pharmaceuticals, a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines, announced the expansion of Icagen’s license agreement with Roche and initiation of a new program focused on a novel ion channel target relevant to neurodegenerative disease.

This new program is an addition to Icagen’s initial neurology program with Roche on another novel CNS target.

Read the press release here.

Read more about Ligand Pharmaceuticals here.

Read more about Roche here.

Image by aymane jdidi from Pixabay

Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at
Alternatively, you can leave your comments on LinkedIn or Twitter.